IL-6 Genomic Variants and Risk of Prostate Cancer
Vol. 16 No. 5 (2019),
21 October 2019
Purpose: To evaluate the role of Interleukin-6 (IL-6) single nucleotide polymorphisms in prostate cancer (PCa) and benign prostate hyperplasia (BPH).
Materials and Methods: We genotyped two IL-6 intronic variants (rs1800795 and rs2069845) in PCa cases, BPH cases and healthy men referred to Labbafinejad and Shohadaye Tajrish Medical Centers using tetra ARMS-PCR method.
Results: The study included 130 PCa cases, 200 BPH cases and 200 healthy men. The C allele of rs1800795 was associated with PCa risk in the assessed population (OR (95% CI) = 1.45 (1.06-1.98)). However, the frequency of rs2069845 variants was not significantly different between PCa, BPH and control groups. The A C haplotype (rs2069845 and rs1800795 respectively) was associated with PCa and BPH risk (OR (95% CI) = 1.67 (1.12- 2.48); OR (95% CI)= 1.78 (1.25 – 2.54)). Besides, the A G haplotype (rs2069845 and rs1800795 respectively) has a protective effect against both PCa and BPH in the assessed population (OR (95% CI) = 0.63 (0.46-0.87); OR (95% CI)= 0.6 (0.45-0.79)).
Conclusion: Consequently, the results of the current study provide further evidence for contribution of IL-6 in prostate cancer.
How to Cite
Miah S, Catto J. BPH and prostate cancer risk. Indian journal of urology : IJU : journal of the Urological Society of India 2014;30:214-218.
Ghafouri-Fard S, Ousati Ashtiani Z, Sabah Golian B, Hasheminasab SM, Modarressi MH. Expression of two testis-specific genes, SPATA19 and LEMD1, in prostate cancer. Archives of medical research 2010;41:195-200.
Taheri M, Habibi M, Noroozi R, et al. HOTAIR genetic variants are associated with prostate cancer and benign prostate hyperplasia in an Iranian population. Gene 2017;613:20-24.
Taheri M, Pouresmaeili F, Omrani MD, et al. Association of ANRIL gene polymorphisms with prostate cancer and benign prostatic hyperplasia in an Iranian population. Biomarkers in medicine 2017;11:413-422.
Faramarzi S, Ghafouri-Fard S. Expression analysis of cancer-testis genes in prostate cancer reveals candidates for immunotherapy. Immunotherapy 2017;9:1019-1034.
Nguyen DP, Li J, Tewari AK. Inflammation and prostate cancer: the role of interleukin 6 (IL-6). BJU international 2014;113:986-992.
Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. The Journal of urology 1999;161:182-187.
Wise GJ, Marella VK, Talluri G, Shirazian D. Cytokine variations in patients with hormone treated prostate cancer. The Journal of urology 2000;164:722-725.
Lee SO, Lou W, Hou M, de Miguel F, Gerber L, Gao AC. Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin Cancer Res 2003;9:370-376.
Brull DJ, Montgomery HE, Sanders J, et al. Interleukin-6 gene -174g>c and -572g>c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arteriosclerosis, thrombosis, and vascular biology 2001;21:1458-1463.
Walston JD, Fallin MD, Cushman M, et al. IL-6 gene variation is associated with IL-6 and C-reactive protein levels but not cardiovascular outcomes in the Cardiovascular Health Study. Human genetics 2007;122:485-494.
Ljungman P, Bellander T, Nyberg F, et al. DNA variants, plasma levels and variability of interleukin-6 in myocardial infarction survivors: results from the AIRGENE study. Thrombosis research 2009;124:57-64.
Pierce BL, Biggs ML, DeCambre M, et al. C-reactive protein, interleukin-6, and prostate cancer risk in men aged 65 years and older. Cancer causes & control : CCC 2009;20:1193-1203.
Kelberman D, Fife M, Rockman MV, Brull DJ, Woo P, Humphries SE. Analysis of common IL-6 promoter SNP variants and the AnTn tract in humans and primates and effects on plasma IL-6 levels following coronary artery bypass graft surgery. Bba-Mol Basis Dis 2004;1688:160-167.
Liu ZQ, Chu L, Fang JM, et al. Prognostic role of C-reactive protein in prostate cancer: a systematic review and meta-analysis. Asian J Androl 2014;16:467-471.
Nakashima J, Tachibana M, Horiguchi Y, et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 2000;6:2702-2706.
Alcover J, Filella X, Luque P, et al. Prognostic Value of IL-6 in Localized Prostatic Cancer. Anticancer Res 2010;30:4369-4372.
Febbraio MA, Ott P, Nielsen HB, et al. Hepatosplanchnic clearance of interleukin-6 in humans during exercise. American journal of physiology Endocrinology and metabolism 2003;285:E397-402.
Vgontzas AN, Bixler EO, Lin HM, Prolo P, Trakada G, Chrousos GP. IL-6 and its circadian secretion in humans. Neuroimmunomodulation 2005;12:131-140.
- Abstract Viewed: 538 times
- pdf/4543 Downloaded: 194 times